These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7850057)

  • 21. The acute phase response in breast carcinoma.
    O'Hanlon DM; Lynch J; Cormican M; Given HF
    Anticancer Res; 2002; 22(2B):1289-93. PubMed ID: 12168939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical evaluation of an immunoradiometric assay for CA15-3 antigen associated with human mammary carcinomas: comparison with carcinoembryonic antigen.
    Fujino N; Haga Y; Sakamoto K; Egami H; Kimura M; Nishimura R; Akagi M
    Jpn J Clin Oncol; 1986 Dec; 16(4):335-46. PubMed ID: 3467106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum ostase in the follow-up of breast cancer patients.
    Marchei P; Santini D; Bianco V; Chiodini S; Reale MG; Simeoni F; Marchei GG; Vecchione A
    Anticancer Res; 1995; 15(5B):2217-22. PubMed ID: 8572628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Usefulness of pyridinium crosslinks and CA 15-3 as markers in metastatic bone breast carcinoma.
    Massidda B; Ionta MT; Foddi MR; Mascia L; Bruder F; Aloi MB; Meleddu C; Giannoni MN
    Anticancer Res; 1996; 16(4B):2221-3. PubMed ID: 8694547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in management techniques and patterns of disease recurrence over time in patients with breast carcinoma treated with breast-conserving therapy at a single institution.
    Pass H; Vicini FA; Kestin LL; Goldstein NS; Decker D; Pettinga J; Ingold J; Benitez P; Neumann K; Rebner M; Dekhne N; Martinez A
    Cancer; 2004 Aug; 101(4):713-20. PubMed ID: 15305400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical value of TPS, CEA and CA 15-3 in breast cancer patients.
    Blijlevens NM; Oosterhuis WP; Oosten HR; Mulder NH
    Anticancer Res; 1995; 15(6B):2711-6. PubMed ID: 8669851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [CA15-3].
    Inaji H
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():651-3. PubMed ID: 16149603
    [No Abstract]   [Full Text] [Related]  

  • 28. Use of TPS and CA 15-3 assays for monitoring chemotherapy in metastatic breast cancer patients.
    Einarsson R; Lindman H; Bergh J
    Anticancer Res; 2000; 20(6D):5089-93. PubMed ID: 11326674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy prolongs the serum CEA-TPA-CA15.3 lead time at the metastatic progression in endocrine-dependent breast cancer patients: a retrospective longitudinal study.
    Nicolini A; Carpi A; Ferrari P; Rossi G
    Cancer Lett; 2008 May; 263(1):122-9. PubMed ID: 18241981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor.
    Babiera GV; Rao R; Feng L; Meric-Bernstam F; Kuerer HM; Singletary SE; Hunt KK; Ross MI; Gwyn KM; Feig BW; Ames FC; Hortobagyi GN
    Ann Surg Oncol; 2006 Jun; 13(6):776-82. PubMed ID: 16614878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer.
    Vinholes J; Coleman R; Lacombe D; Rose C; Tubiana-Hulin M; Bastit P; Wildiers J; Michel J; Leonard R; Nortier J; Mignolet F; Ford J
    Br J Cancer; 1999 Apr; 80(1-2):221-8. PubMed ID: 10390000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [CA15-3 tumor marker in early detection of breast cancer].
    Roisman I; Shiloni E; Lifshiz I; Shoshani D; Saphir D; Honigman I; Livni N; Sherman Y; Papo O; Durst AL
    Harefuah; 1992 Feb; 122(4):213-8. PubMed ID: 1563679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients.
    Laessig D; Nagel D; Heinemann V; Untch M; Kahlert S; Bauerfeind I; Stieber P
    Anticancer Res; 2007; 27(4A):1963-8. PubMed ID: 17649806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of TPS with CEA and CA 15.3 in follow-up of Chinese breast cancer patients.
    Hu XC; Day W; Jones B; Loo WT; Chow LW
    Anticancer Res; 2002; 22(3):1865-8. PubMed ID: 12168883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of soluble CD44 splice variant v5 in the diagnosis and follow-up in breast cancer patients.
    Kittl EM; Ruckser R; Selleny S; Samek V; Hofmann J; Huber K; Reiner A; Ogris E; Hinterberger W; Bauer K
    Exp Clin Immunogenet; 1997; 14(4):264-72. PubMed ID: 9523162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preoperative high type I collagen degradation marker ICTP reflects advanced breast cancer.
    Keskikuru R; Kataja V; Kosma VM; Eskelinen M; Uusitupa M; Johansson R; Risteli L; Risteli J; Jukkola A
    Anticancer Res; 1999; 19(5C):4481-4. PubMed ID: 10650796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumour marker measurements in the diagnosis and monitoring of breast cancer.
    Cheung KL; Graves CR; Robertson JF
    Cancer Treat Rev; 2000 Apr; 26(2):91-102. PubMed ID: 10772967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma.
    Lê MG; Arriagada R; Spielmann M; Guinebretière JM; Rochard F
    Cancer; 2002 Jun; 94(11):2813-20. PubMed ID: 12115367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immunoradiometric assay of tumor marker CA15-3 and its clinical application].
    Chen Z; Fan Z; Yang J
    Zhonghua Zhong Liu Za Zhi; 1998 Mar; 20(2):125-8. PubMed ID: 10920962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
    Gong Y; Booser DJ; Sneige N
    Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.